» Articles » PMID: 21104160

Molecular Mechanisms of Leukemia-associated Protein Degradation

Overview
Journal Front Med China
Specialty General Medicine
Date 2010 Nov 25
PMID 21104160
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Chemical biology, using small molecules as probes to study the cellular signaling network, has developed rapidly in recent years. The interaction between chemistry and biology not only provides new insight into the understanding of cellular activities, but also generates new lead compounds for the treatment of diseases. Transcription factors and kinases such as retinoic acid receptor-alpha (RARα), acute myeloid leukemia 1 (AML1), CAAT/enhancer-binding protein α (C/EBPα), c-myc, and c-abl play important roles in the differentiation of hematopoietic stem/progenitor cells. Abnormalities in these proteins may cause the dysregulation of hematopoiesis and even the occurrence of leukemia. Ubiquitin-mediated protein degradation represents a critical mechanism in regulating the cellular levels and functions of these proteins. Thus, targeting protein degradation has been emerging as an important strategy to conquer malignant diseases. In this review, we will summarize the recent advances in the understanding of the roles of protein degradation in leukemia, with an emphasis on the mechanisms revealed by small molecules.

Citing Articles

Targeting Protein Degradation Pathways in Tumors: Focusing on their Role in Hematological Malignancies.

Wolska-Washer A, Smolewski P Cancers (Basel). 2022; 14(15).

PMID: 35954440 PMC: 9367439. DOI: 10.3390/cancers14153778.


Effector caspases and leukemia.

Lu Y, Chen G Int J Cell Biol. 2011; 2011:738301.

PMID: 21647292 PMC: 3103908. DOI: 10.1155/2011/738301.

References
1.
Jin Y, Jeon E, Li Q, Lee Y, Choi J, Kim W . Transforming growth factor-beta stimulates p300-dependent RUNX3 acetylation, which inhibits ubiquitination-mediated degradation. J Biol Chem. 2004; 279(28):29409-17. DOI: 10.1074/jbc.M313120200. View

2.
Niu C, Yan H, Yu T, Sun H, Liu J, Li X . Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood. 1999; 94(10):3315-24. View

3.
Scandura J, Boccuni P, Cammenga J, Nimer S . Transcription factor fusions in acute leukemia: variations on a theme. Oncogene. 2002; 21(21):3422-44. DOI: 10.1038/sj.onc.1205315. View

4.
Naka K, Hoshii T, Hirao A . Novel therapeutic approach to eradicate tyrosine kinase inhibitor resistant chronic myeloid leukemia stem cells. Cancer Sci. 2010; 101(7):1577-81. PMC: 11159883. DOI: 10.1111/j.1349-7006.2010.01584.x. View

5.
Boe S, Simonsen A . Autophagic degradation of an oncoprotein. Autophagy. 2010; 6(7):964-5. DOI: 10.4161/auto.6.7.13066. View